DelMar Pharmaceuticals recently hosted a Key Opinion Leader forum at the Lotte New York Palace Hotel in New York City, highlighting its novel treatment for patients suffering from glioblastoma multiforme (GBM).
Dr. James Perry, the chair of the Canadian Brain Tumour Consortium and the Head of Neurology at Sunnybrook Health Sciences Centre in Toronto, delivered a presentation at the forum. He discussed the treatment landscape for GBM patients and gave an overview of VAL-083, DelMar’s small-molecule chemotherapeutic addressing multiple forms of cancer, including MGMT-unmethylated and refractory GBM.
GBM, the company noted in its press release, is the most common and most lethal form of brain cancer.
Dr. Perry is well-versed in neuro-oncology research. He is the Crolla Endowed Chair of Brain Tumour Research at Sunnybrook Odette Cancer Centre's Hurvitz Brain Sciences Program, Ontario Lead in CNS Oncology and a Professor of Medicine at University of Toronto.
The event was attended by institutional investors, sell-side analysts, investment bankers, and business development professionals. An archived webcast of the event, with slides, is available online on the investors section of DelMar’s website.